A Clinical Trial about the Efficacy of Pimobendan in Comparison to Enalapril in Dogs with Mitral Valve Endocardiosis. Part 2: Echocardiographic Results
WSAVA 2002 Congress
*Michael Deinert, Anja Ripken
*Tierklinik Am Sandpfad, Dr. Walla & Partner
Wiesloch, Baden-Württemberg DE
m.deinert@tierklinik-sandpfad.de

OBJECTIVES

The echocardiographic examination was performed to compare the effects of the two drugs on heart chamber size and wall motion. Of special interest was the development or the increase of a hyperkinetic wall motion pattern in the Pimobendan group compared to the Enalapril group. Please refer also to Part 1.

MATERIALS

The echocardiographic parameters measured on day 0, 7 and 28 of the study consisted of left atrial to aortic ratio, left ventricular wall thickness and diameters (LVID) and calculations from these values i.e., FS (fractional shortening) and ESVI (end systolic volume index). Please refer also to Part 1.

RESULTS

Within the Pimobendan group no significant difference in the echocardiography parameters were seen. On the other hand we found significant enlargements (p < 0,05) of LVIDd, LVIDs and ESVI within the Enalapril group after 28 days. The comparison between the groups showed significantly larger (p < 0,05) LVIDd and ESVI on day 7 and significantly larger (p < 0,05) LVIDd and LVIDs on day 28 in the Enalapril group. The FS calculations showed no significant changes within or between the groups (Enalapril group: Day 0: 44,4 %, day 28: 40,9 %; Pimobendan group: Day 0: 47,1 %, day 28: 46,7 %; ns)

CONCLUSION

According to our echocardiographic data treatment with Enalapril lead to a significant increase of the left ventricular diameters. This effect did not occur in the Pimobendan group. Treatment with Pimobendan on the other hand did not lead to an increase of the fractional shortening nor occurred a hyperkinetic wall motion pattern, the related parameters showed no significant changes. Also from this echocardiographic data, it can be concluded, that Pimobendan is a safe and efficacy drug for the treatment of patients with mitral valve endocardiosis.

The increase of left ventricular diameters (LVID) in the Enalapril group may be caused by the slower heart rate in this group allowing a longer filling period. But it could also be interpreted as a sign of left ventricular compensation for the mitral regurgitation that does not occur with Pimobendan treatment.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Anja Ripken
Veterinary Clinic Bremen, Dürr/Rosenhagen
Schwachhauser Ring 86
Bremen, Bremen 28209 DE

Michael Deinert
Tierklinik Am Sandpfad, Dr. Walla & Partner
Ludwig-Wagner-Str.31
Wiesloch, Baden-Württemberg 69168 DE


MAIN : : Pimobendan in Comparison in Endocardiosis. Part 2
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27